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The use of c-abl-speciﬁc inhibitors such as Imatinib (IM)
or Dasatinib has revolutionized the treatment of chronic
myeloid leukemia (CML). However, a signiﬁcant percen-
tage of patients become resistant to IM. In this report, we
have analyzed the possibility of using the proteasome as a
molecular target in CML. Our results show that cells that
express Bcr-Abl1 are more sensitive to the inhibition of
the proteasome with Bortezomib (Btz) than control cells.
This treatment reduces the proliferation of Bcr-Abl1-
expressing cells, by inactivating NF-jB2 and decreasing
the phosphorylation of Rb, eventually leading to an
increase in caspase-dependent apoptosis. Furthermore,
we show that Btz also induces cell-cycle arrest and
apoptosis in cells expressing Bcr-Abl1 mutants that are
resistant to IM. These results unravel a new molecular
target of Btz, that is the Rb pathway, and open new
possibilities in the treatment of CML especially for
patients that become resistant to IM because of the
presence of the T315I mutation.
Oncogene (2010) 29, 3276–3286; doi:10.1038/onc.2010.81;
published online 22 March 2010
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Introduction
Chronic myeloid leukemia (CML) appears as a con-
sequence of the reciprocal translocation between chro-
mosomes 9 and 22, giving rise to the expression of the
Bcr-Abl1 oncoprotein. Current treatment of the disease
includes the use of the speciﬁc tyrosine-kinase inhibitor
Imatinib (IM). Even though treatment with IM induces
complete cytogenetic remission in 470% of CML
patients, the appearance of Bcr-Abl1 mutants resistant
to IM remains a signiﬁcant problem (Druker, 2008).
This resistance arises mainly by point mutations in the
ATP-binding pocket at the active site of the tyrosine-
kinase Abl, which reduces the afﬁnity for IM without
changing the afﬁnity for ATP (Shah and Sawyers, 2003).
Second generation inhibitors, such as Dasatinib and
Nilotinib, have been proven efﬁcient against most Bcr-
Abl1 mutants, but the T315I mutant remains insensitive
to the new inhibitors (Ramirez and DiPersio, 2008).
We have earlier reported that Bcr-Abl1 induces the
degradation of the cell-cycle inhibitor p27Kip1 by the
proteasome, through the induction of the F-box protein
Skp2 (Andreu et al., 2005). These results prompted us to
explore the possibility of using the proteasome as a
potential therapeutic target in the treatment of CML.
The use of the proteasome inhibitor Bortezomib (Btz)
has been successful in the treatment of multiple
myeloma and mantle cell lymphoma (Chauhan et al.,
2008; Wei and Roberts, 2008). Recently, it has also been
shown that Bcr-Abl1 induces the activity of the
proteasome, again supporting the idea of using the
proteasome as a suitable target in Bcr-Abl1-expressing
cells (Crawford et al., 2009).
In this report, we have analyzed the effect of Btz on
proliferation and survival of different cells expressing Bcr-
Abl1, such as the murine BaF/3 cell line stably transduced
with Bcr-Abl1, the human blast crisis-derived TCC-S cell
line, and primary CD34þ cells from CML patients. We
have also used BaF/3 cells expressing mutant forms of Bcr-
Abl1 that confer resistance to IM, including the highly
resistant T315I mutant. Our results show that Bcr-Abl1-
expressing cells, including the IM-resistant ones, are more
sensitive to Btz than control cells and that Btz treatment
reduces proliferation and induces caspase-dependent apop-
tosis. We have also analyzed the molecular mechanisms
responsible for the effect of Btz in these cells. Our results
underscore the effect of Btz on the Rb pathway of cell-cycle
control and support the use of Btz in the treatment of
CML, particularly for those patients that become resistant
to IM as a consequence to the T315I mutation.
Results
Btz inhibits proliferation of Bcr-Abl1-expressing cells
To test the possibility of using the proteasome as a
therapeutic target in the treatment of CML, we treated
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control BaF/3 cells and BaF/3 cells that stably express
wt Bcr-Abl1 p210 (BaF/3-p210) with different doses of
the proteasome inhibitor Btz, ranging from 0 to 100 nM.
Btz is lethal above 10 nM on both cell lines (not shown).
The dose-response analysis between 0 and 10 nM Btz
reveals that the Bcr-Abl1-expressing BaF/3 cells are
more sensitive to Btz than the parental BaF/3 cells
(Figure 1a). The difference between BaF/3-p210 and
control BaF/3 cells is statistically signiﬁcant (Po0.05) at
5, 6, and 7 nM Btz. The IC50 values are 6.2 and 4.7 nM at
48 h and 7.2 and 5.3 nM at 72 h for BaF/3 and BaF/
3-p210 cells, respectively. As the maximal difference
between BaF/3 and BaF/3-p210 at 72 h is seen with the
dose of 6 nM, this is the dose we decided to use for the
rest of the experiments.
We also wanted to analyze the sensitivity of human
cells to Btz. We chose the TCC-S cell line, which has
been earlier used as a model of Phþ cells (Kano et al.,
2007; Roman-Gomez et al., 2007). These cells derive
from a CML patient in blast crisis and express mainly
the p210 form of Bcr-Abl1. This cell line is more
sensitive than the other two cell lines tested, with IC50
values of 2.8 nM at 48 h and 3.7 nM at 72 h (Figure 1a).
We then compared the effect of a 6-nM dose of Btz on
the growth curve of BaF/3 and BaF/3-p210 cells. As
shown in Figure 1b, Btz treatment initially reduces the
proliferation of control BaF/3 cells at 24–48 h, but they
recover in the 48–72 h period. However, Bcr-Abl1-
expressing BaF/3 cells show a permanent growth arrest
for the length of the experiment. The smaller effect of
Btz on BaF/3 compared with BaF/3-p210 cells could be
due to the fact that control cells are cultured in the
presence of IL3. However, when we add IL3 to the BaF/
3-p210 cells, the effect of Btz is indistinguishable from
that shown in the absence of IL3 (Figure 1b). Therefore,
the sensitivity to Btz is not a consequence of the
different culture conditions, but most likely because of
the expression of Bcr-Abl1. In the case of the TCC-S cell
line, we compared the effect of Btz with that of IM.
First, we calculated the IC50 of IM for this cell line,
getting a value of 0.2 mM (not shown). Figure 1c shows
that the treatment with 6 nM Btz causes the same growth
inhibition as the treatment with 0.3 mM IM. The
difference between untreated and Btz-treated cells is
statistically signiﬁcant (Po0.01) both at 48 and 72 h in
the BaF/3-p210 and TCC-S cell lines, but not in the
parental BaF/3 cell line (Figure 1d). These results show
that Bcr-Abl1-expressing cells are more sensitive to Btz
treatment than control cells.
We then explored the possible synergy between Btz
and IM. We used a ﬁx ratio of doses ranging from 1 to
5 nM Btz and from 0.1 to 0.5 mM IM, around the IC50 for
each one of them in the BaF/3-p210 cell line. The
combination index obtained using the Chou–Talalay
method indicates that there is an additive effect of both
drugs, but no synergism, at least under our experimental
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Figure 1 Btz inhibits proliferation of Bcr-Abl1-expressing cells. (a) Dose response of Btz on BaF/3, BaF/3-p210, and TCC-S cell lines.
Cells were seeded at a density of 1 105/ml and treated with a single dose of Btz ranging from 0 to 10 nM. Viable cell counts at 72 h were
used to plot the dose-response effect. Cell counts relative to control (100%) from four different experiments are represented as
mean±s.d. Differences between BaF/3 and BaF/3-p210 cells are statistically signiﬁcant at 5, 6, and 7 nM, as revealed by a one-way
analysis of variance followed by a Tukey’s multiple comparison test (Po0.01). Note that the maximal difference between BaF/3 and
BaF/3-p210 is at 6 nM Btz. (b) Effect of Btz on the proliferation of BaF/3 and BaF/3-p210. Growth of untreated (C) and Btz-treated
(6 nM, Btz) cells was followed by viable cell count every 24 h. Mean±s.d. from four different experiments is shown. Addition of 10%
WEHI-conditioned medium to the culture medium of BaF/3-p210 cells as a source of murine IL-3 (p210 IL3 Btz) does not prevent the
effect of Btz on these cells. (c) The effect of 6 nM Btz is similar to that of 0.3 mM IM on the human-derived TCC-S cell line. Cells were
treated and counted as in (b). The dose of 0.3mM IM was selected from an earlier dose-response experiment (not shown). (d) Differences
between untreated (C) and Btz-treated (Btz) cells from (b) and (c) at 48 and 72 h are plotted as columns (meanþ s.d.). Student’s t-test
analysis revealed statistically signiﬁcant differences between Btz and C at 48 and 72 h only in Bcr-Abl1-expressing cells, but not in BaF/
3 cells (**Po0.01).
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conditions (data not shown). As IM and Btz have
additive effects, this would suggest that the activation of
the proteasome in Bcr-Abl1-expressing cells is a
consequence of Bcr-Abl1-kinase activity.
IM-resistant Bcr-Abl1-expressing cells are also sensitive
to Btz
To see whether Btz could have an effect on cells
expressing IM-resistant forms of Bcr-Abl1, we used
BaF/3 cells expressing four different mutants of Bcr-
Abl1: T315I, Q252H, Y253F, and E255K. Q252H is
only partially resistant to IM and is affected by the drug
at high doses. The highly resistant T315I mutation
affects the direct contact between IM and Bcr-Abl1,
therefore, preventing this interaction (Shah and Saw-
yers, 2003). We cultured these cell lines in parallel with
the one expressing wt Bcr-Abl1 (BaF/3-p210) and
treated them with a single 6 nM dose of Btz. As shown
in Figure 2, Btz inhibits proliferation of all these Bcr-
Abl1-expressing cell lines to the same extent, indicating
that Btz is equally effective against IM-sensitive and
-resistant Bcr-Abl1-expressing cells. One-way analysis of
variance followed by Tukey’s analysis revealed that all
the mutant cell lines behave the same as the BaF/3-p210
one, and that there are statistically signiﬁcant differences
between untreated and treated groups at 48 and 72 h
(Po0.01).
Btz inhibits S-phase entry in Bcr-Abl1-expressing cells
We then wanted to characterize the effect of Btz on the
cell cycle of these cells. DNA proﬁles of BaF/3 control
and BaF/3-p210 cells show that 48 h after the addition
of Btz, there is an accumulation of the Bcr-Abl1-
expressing cells in the G0/G1 phase of the cell cycle,
whereas control cells are minimally affected (Figure 3a).
We also analyzed the cell-cycle proﬁle of mutant Bcr-
Abl1-expressing cells (Figure 3a). In all cases, there is a
reduction of the proliferating populations (SþG2/M)
and an accumulation of cells in G0/G1. The DNA
proﬁles also show that Btz induces cell death, as there is
an increase in the sub-G0/G1 population.
To characterize the nature of the cell-cycle arrest in
more detail and quantify the percentage of cells in each
of the cell-cycle phases more precisely, we performed an
5-ethynyl-20-deoxyuridine (EdU) incorporation assay.
Figure 3b shows an example of this analysis with BaF/3
and BaF/3-p210 cells. In BaF/3 cells, there is a slight
reduction of the S-phase population at 24 h, but the cells
have recovered at 48 h after the addition of Btz. In
contrast, there is a big decrease of the S-phase
population in the BaF/3-p210 cells that is permanent.
Quantiﬁcation of the EdU incorporation experiments
(Figure 3c) reveals that 48 h after Btz addition, the cell-
cycle proﬁle of control BaF/3 cells is not statistically
different from untreated cells. In contrast, all the cell
lines expressing Bcr-Abl1, including the mutant forms
that are IM resistant, display a G0/G1 arrest when
treated with Btz. The differences between Btz-treated
cells and the untreated controls are statistically
signiﬁcant in the G0/G1 accumulation (Po0.05 in all
cases) and also in the S-phase reduction (Po0.01 in
all cases).
Btz treatment reduces the phosphorylation and the activity
of Rb in Bcr-Abl1-expressing cells
At the molecular level, Rb phosphorylation regulates
the transition from G1 into S phase (Khidr and Chen,
2006). Therefore, we analyzed the effect of Btz on the
phosphorylation status of Rb by western blot. As shown
in Figure 4a, Btz treatment causes a reduction in the
total level of Rb protein, both in BaF/3 and in BaF/
3-p210 cells. However, in the case of the BaF/3-p210 and
not the BaF/3 cells, a faster migrating band, corre-
sponding to the hypo-phosphorylated form of Rb (Rb),
can be detected. At the same time, there is a decrease in
the intensity of the slower migrating bands, correspond-
ing to hyper-phosphorylated Rb (P-Rb). This change in
the phosphorylation status of Rb can be detected as
early as 12 h and is more evident at 24 h (Figure 4a). If
we represent the ratio between the hypo-phosphorylated
and the hyper-phosphorylated forms of the protein (Rb/
P-Rb), the increase in this ratio is statistically signiﬁcant
at 12 and 24 h after Btz addition compared with time 0 h
(Po0.05; Figure 4c). We compared this effect with that
of the Bcr-Abl1-kinase inhibitor IM. As earlier reported
(Andreu et al., 2005), IM also increases the level of
hypo-phosphorylated Rb, ﬁnally inducing the disap-
pearance of the hyper-phosphorylated forms of the
protein (Figure 4a).
Rb regulates the expression of cyclins such as cyclin A
(CycA), through the E2F family of transcription factors.
Therefore, the expression of CycA reﬂects the activity of
Rb. As shown in Figure 4a, the amount of CycA protein
decreases as the levels of P-Rb also decrease upon Btz or
IM treatment, conﬁrming that the effect of these drugs
on Rb is also functional. Rb phosphorylation is
mediated by Cyclin/Cdk complexes active during G1
(Murray, 2004). The activity of these complexes is in
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Figure 2 Btz inhibits proliferation of cells expressing Bcr-Abl1
mutants that confer resistance to IM. BaF/3-expressing wt Bcr-
Abl1 (p210), or different mutants of the protein (T315I, Q252H,
Y253F, and E255K) untreated (C) or treated with 6 nM Btz (Btz)
were seeded and counted as in Figure 1. Mean±s.e.m. is
represented from a total of eight different experiments. There are
no statistical differences among control cells or among treated cells,
but in each cell line, the difference between treated and untreated is
signiﬁcant, as revealed by a one-way analysis of variance followed
by a Tukey’s multiple comparison test (Po0.01).
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turn negatively regulated by inhibitors of the Cip/Kip
family, such as p21Cip1 (p21) and p27Kip1 (p27) (Sherr
and Roberts, 2004). As shown in Figure 4a, Btz
treatment results in the accumulation of both cell-cycle
inhibitors. p21 accumulates both in control and Bcr-
Abl1-expressing cells. However, in BaF/3 cells, there is
only a slight accumulation of p27 at 12 h and not later
on, whereas in BaF/3-p210 cells, p27 accumulation
increases with time. In contrast, IM treatment only
induces the accumulation of p27 and causes a reduction
in p21 expression.
In the case of IM-resistant Bcr-Abl1-expressing BaF/
3 cells, Btz not only induces a decrease in the level of
total Rb, but also of P-RB (Figure 4b). In fact, the
increase of the Rb/P-RB ratio is higher than the
decrease of total Rb (Figure 4c). In every case, the P-
Rb decrease is detected at 12 h and the effect is more
evident at 24 h (Figures 4b and c). Similar to the BaF/3-
p210 cells, the mutant Bcr-Abl1-expressing cell lines also
display a decrease in CycA expression and an increase in
p21 and p27 protein levels (Figure 4b). Therefore, the
effect of Btz at the molecular level on the cell-cycle
regulatory machinery of cells expressing Bcr-Abl1 is the
same regardless to the IM sensitivity of the cells.
Btz prevents the activation of NF-kB
One of the known targets of Btz in different models is
the transcription factor NF-kB (Galimberti et al., 2008).
We assayed the effect of Btz on the activity of this
protein by electrophoretic mobility shift assay and
found that Btz reduces the DNA-binding activity of
NF-kB on BaF/3 and Ba/F3-p210 cells with no
signiﬁcant differences between both cell types
(Figure 5a). Therefore, the activity of this transcription
factor does not seem to be responsible for the cell-cycle
arrest that we see only in BaF/3-p210 cells. As the initial
level of NF-kB activity is higher in BaF/3-p210 cells, we
cannot rule out the possibility that the disappearance of
NF-kB activity has a bigger impact on these cells. There
are two alternative pathways of NF-kB activation: the
canonical and the non-canonical pathways (Pomerantz
and Baltimore, 2002). The second one involves the
proteasome-dependent activation of NF-kB2 from a 100
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Figure 3 Btz induces a G1 cell-cycle arrest in Bcr-Abl1-expressing cells. (a) BaF/3 cells and derivatives expressing wt Bcr-Abl1 (p210)
and different IM resistant mutants (T315I, Q252H, Y253, and E255K), untreated (C, left) or treated with 6 nM Btz (Btz, right) for 48 h
were ﬁxed, stained with PI, and analyzed by ﬂow cytometry as described in Materials and methods. The experiment shown is a
representative example from six different experiments. (b) and (c) To quantify the different cell-cycle populations in each case, cells
received a 30-min pulse of the nucleotide analog EdU. EdU/PI double staining allows for an accurate quantiﬁcation of cells in G0/G1,
S, and G2/M. An example of this kind of analysis for BaF/3 and BaF/3-p210 cells at 0, 24, and 48 h after the addition of 6 nM Btz is
shown in (b). Quantiﬁcation of such experiments (n¼ 3) with BaF/3, BaF/3-p210, and the IM-resistant Bcr-Abl1-expressing BaF/3 cells
at 48 h is represented in (c) as meanþ s.d. There are no signiﬁcant differences between C and Btz-treated BaF/3 cells (the G0/G1–S–
G2/M values are 24±11–58±7–16±5 for untreated cells and 32±4–45±2–20±7 for Btz-treated cells). In all other cases, Student’s
t-test reveals that there are statistically signiﬁcant differences indicating an increase in G0/G1 (Po0.05) and a decrease in S phase
(Po0.01) in Btz-treated cells compared with each control (as an example, for the BaF/3-p210 cells, the G0/G1 – S – G2/M values are
39±7–54±7–5.4±0.8 for untreated cells and 68±9–6±2–7±3 for Btz-treated cells).
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Figure 4 Btz treatment decreases the phosphorylation and the function of Rb in Bcr-Abl1-expressing cells. (a) Control BaF/3 (left) and
Bcr-Abl1-expressing BaF/3-p210 (right) cells were treated with 2mM IM or 6nM Btz for 12 and 24h or untreated (C) and cell extracts were
prepared and analyzed by western blot with the appropriate primary antibodies, as indicated. In the Rb blot (top), the faster migrating band
corresponds to the hypo-phosphorylated form of Rb (Rb), whereas the slower migrating bands correspond to the hyper-phosphorylated
forms of the protein (P-Rb). b-tubulin is used as a loading control. Shown is a representative blot of three independent experiments.
(b) Similar analysis as in (a) was performed with extracts from untreated (C) and treated with 6nM Btz for 12 and 24h BaF/3 cells expressing
four different Bcr-Abl1 mutants that confer IM resistance. A single band is detected in the p27 blot because a different antibody was used
that does not detect the lower band seen in (a). (c) Btz treatment reduces the amount of total Rb as well as its phosphorylation. P-Rb and
total Rb bands were quantiﬁed using the QuantityOne software (Bio-Rad). Columns represent meanþ s.d. relative to the values at t¼ 0
(value of 1) from three independent experiments as the ones shown in (a, b). Both total Rb and the Rb/P-RB ratio are represented. Student’s
t-test reveals that the differences between Btz and control cells are signiﬁcant as early as 12h in most cases (*Po0.05; **Po0.01).
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to 52 kDa form (Heusch et al., 1999). As Btz could be
affecting this activation, we analyzed the processing and
activation of NF-kB2 in our experimental system by
western blot. As shown in Figure 5b, BaF/3-p210 cells
exhibit a higher level of processed, active p52-NF-kB2
protein than BaF/3 control cells. However, on Btz
treatment, there is a marked reduction in the level of the
52-kDa active form of NF-kB2.
It has been shown that the NF-kB2 subunit is relevant
for the regulation of Skp2 and c-Myc expression (Barre
and Perkins, 2007). It is known that these two proteins
are among the many factors that regulate the levels and
activity of the cell-cycle inhibitors p21Cip1 and p27Kip1
(Perez-Roger et al., 1999; Kossatz et al., 2004). On the
other hand, Bcr-Abl1-kinase activity inhibition with IM
results in the downregulation of both Skp2 and c-Myc,
indicating that these two proteins are molecular targets
of Bcr-Abl1 (Sawyers, 1993; Andreu et al., 2005).
Therefore, we analyzed the effect of Btz on Skp2 and
c-Myc and found that both show lower levels in Btz-
treated cells expressing Bcr-Abl1, with no signiﬁcant
change in BaF/3 control cells (Figure 5b).
Btz induces caspase-dependent apoptosis
of Bcr-Abl1-expressing cells
Treatment with Btz in different tumor models induces
apoptosis in vitro (Brignole et al., 2006; Perez-Galan
et al., 2006; Stapnes et al., 2007; Strauss et al., 2007;
Galimberti et al., 2008; Zhao et al., 2008). As noted
earlier, Btz induces an increase of the sub-G0/G1
population (Figure 3a). To evaluate the effect of Btz
on the survival of Bcr-Abl1-expressing cells, we double
stained the cells with Annexin-V and propidium iodide
(PI) to distinguish between apoptosis and necrosis and
analyzed them by ﬂow cytometry. The results shown in
Figure 6a indicate that Btz treatment induces apoptosis
in Bcr-Abl1-expressing cells, as indicated by the increase
in the Annexin V positive population. In the case of
BaF/3 cells, there is an initial increase in the apoptotic
population at 24 h, but then it decreases at 48 and 72 h.
The difference between BaF/3-p210 and control BaF/3
cells is statistically signiﬁcant at 48 and 72 h (Po0.01).
To test the caspase dependency of the apoptosis induced
by Btz in our model, we used the pan-caspase inhibitor
z-VAD and analyzed apoptosis by measuring the
appearance of the sub-G0/G1 apoptotic population in
the DNA proﬁle (Figure 6b). Pre-treatment of the cells
with this inhibitor partially abrogates the cell death
induced by Btz, suggesting that caspase activation is at
least in part necessary for the induction of apoptosis by
Btz. In the IM-resistant Bcr-Abl1-expressing cells, Btz
also induces apoptosis and it can be partially prevented
by z-VAD pre-treatment (Figure 6b). Quantiﬁcation of
the sub-G0/G1 apoptotic population gives a statistically
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oligonucleotide with the consensus sequence for NF-kB was incubated with nuclear extracts from control BaF/3 (top) and Bcr-Abl1-
expressing BaF/3-p210 (bottom) cells treated with 6 nM Btz for the times indicated. The DNA-binding activity of NF-kB in those
extracts was analyzed by electrophoretic mobility shift assay. O: labeled oligonucleotide without extract. C: binding was competed with
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one shown on the left. Columns represent the meanþ s.d. of the intensity of the bands relative to time 0 h. (b) BaF/3 and BaF/3-p210
cells were treated with 6 nM Btz for the indicated times and cell extracts were prepared and analyzed by western blot with the indicated
antibodies. The antibody against NF-kB2 recognizes both the 100 kDa (inactive) and the 52 kDa (active) forms of the protein.
b-tubulin is used as a loading control. A representative blot of three different experiments is shown.
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signiﬁcant difference at 24 and 48 h after Btz treatment
compared with time 0 h in all cell lines. In addition, the
anti-apoptotic effect of z-VAD is signiﬁcant in all cases
(Figure 6c).
Finally, we tested whether Btz could have an effect on
primary CD34þ cells from a CML patient. As a
control, we used primary non-CML CD34þ cells from
umbilical cord. We treated the cells with 6 and 10 nM Btz
and analyzed the cell-cycle proﬁle by PI staining
(Figure 7). Even though control cells show some cell
death, the CML CD34þ cells are more sensitive, with a
marked decrease in proliferation and an increase in the
sub-G0/G1 population (20% in control to 60% at 6 nM),
whereas control CD34þ cells show a smaller effect
(30% cell death at 6 nM). This result conﬁrms that
Bcr-Abl1-expressing cells are more sensitive to the
proteasome inhibitor Btz.
Discussion
In this report, we have explored the possibility of
inhibiting the proteasome in the treatment of CML and
analyzed the changes induced by Btz on the molecular
mechanisms controlling cell proliferation and survival.
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Our results show that Btz induces a cell-cycle arrest and
also apoptosis in Bcr-Abl1-expressing cells and not in
control cells. The event of apoptosis can be partially
prevented with the pan-caspase inhibitor z-VAD in-
dicating the implication of caspases in Btz induced
apoptosis in the cell models we have used. Regarding
the effect of Btz on proliferation, this inhibitor
blocks entry into S phase. This is not only shown
by our cell-cycle analysis, but also by preventing
apoptosis with the caspase inhibitor z-VAD: the cells
treated with this inhibitor display an absence of cells in S
phase, with the accumulation of the cells in G0/G1 and
in G2/M. This indicates that the effects of Btz on
proliferation and survival can be separated and suggests
that the apoptosis could be a consequence of the
cell-cycle arrest.
At the molecular level, the effect of Btz is character-
ized by a decrease in the phosphorylation status and
later processing of Rb, the latter being related to the
apoptosis induced by Btz. We propose that the G1 cell-
cycle arrest induced by the inhibition of the proteasome
by Btz is the consequence of a series of events involving
the failure in the activation of NF-kB2 with a decrease
in the expression of c-Myc and Skp2 that results in the
accumulation of p21 and p27, inhibitors of the kinase
activity of G1 Cyclin/Cdk complexes. As a result, Rb is
not correctly maintained in its phosphorylated form and
keeps E2F sequestered and inactive, reducing the
expression of CycA and preventing S-phase entry. On
the other hand, Btz induces the activity of caspases
involved in apoptosis and these proteases are also
responsible for the proteolitic cleavage of Rb inactivat-
ing the anti-apoptotic function of this protein (Janicke
et al., 1996).
There are some works reporting that Btz inhibits
growth of Bcr-Abl1-expressing cells. Most of them use
Btz in combination with other drugs (Yu et al., 2003;
Dai et al., 2004; Dasmahapatra et al., 2006; Yan et al.,
2007) or lack the use of control cells (Gatto et al., 2003).
In our case, we have used Btz alone at a dose that has no
effect on BaF/3 cells that do not express Bcr-Abl1,
showing that Btz alone is sufﬁcient to arrest the cell
cycle and induce apoptosis speciﬁcally in Bcr-Abl1-
expressing cells. The use of control cells reinforces the
idea of the higher sensitivity of tumor cells to the
inhibition of the proteasome (Joazeiro et al., 2006; Vink
et al., 2006). We also show that Btz is able to induce the
same effects on cells expressing mutant forms of Bcr-
Abl1 that confer resistance to IM. These effects are
indistinguishable from the ones seen with IM-sensitive
Bcr-Abl1-expressing cells. Moreover, Btz is able to
induce apoptosis also in the kinase inhibitor-resistant
mutant T315I.
We also show that Btz is effective in primary CD34þ
cells from a CML patient. Very recently, Heaney and
co-workers have also shown that Btz induces apoptosis
of primary CD34þ cells and also the more primitive
CD34þ 38-cells from CML patients. These authors
show that Btz reduces (1) the capacity of these cells to
form colonies in long-term cultures and (2) the engraft-
ment potential of these human CD34þ CML cells
(Heaney et al., 2010). This indicates that Btz can target
CML stem cells that are resistant to IM treatment.
NF-kB is commonly inactive in Btz-treated cells
(Adams, 2001; Sartore-Bianchi et al., 2007; Galimberti
et al., 2008; Markovina et al., 2008; Ocio et al., 2008;
Yang et al., 2008). In our case, Btz reduces the DNA-
binding activity of NF-kB in control and Bcr-Abl1-
expressing cells. Therefore, this protein does not seem to
be responsible for the effects we see only in Bcr-Abl1-
expressing cells. However, there is a difference in the
effect of Btz on the activation of NF-kB2 that could be
responsible for the cell-cycle arrest and, perhaps, also
the caspase-dependent apoptosis that we observe. We
show the inactivation of NF-kB2 by Btz in a direct way,
by measuring the level of processing from the inactive
100 kDa form to the active 52 kDa form, and also
indirectly, by analyzing the expression levels of two
known targets of NF-kB2, namely Skp2 and c-Myc.
This result establishes a new link between Bcr-Abl1 and
the NF-kB2 signaling pathway that is sensitive to
proteasome inhibition in CML cells.
In summary, this work shows that Btz reduces the
proliferation and survival of Bcr-Abl1-expressing cells,
regardless of their sensitivity to IM and including the
highly resistant mutant T315I. Our results also show
that the inhibition of the proteasome affects the Rb
pathway through the inactivation of NF-kB2. This, in
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Figure 7 Btz induces cell death in primary CD34þ cells from a
CML patient. Control CD34þ cells from umbilical cord (Control
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CD34þ , right) were seeded at 1 106 cells/ml and treated with 6
and 10 nM Btz or untreated (C). After 48 h, cells were stained with
PI and the cell-cycle proﬁle was analyzed by ﬂow cytometry.
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turn, reduces the level of Skp2 and c-Myc. The central
functions of these two potent oncoproteins in regulating
the cell cycle indicates that Btz is affecting important
pathways that are usually altered in tumor cells,
suggesting that this drug could have potential uses not
only in CML but also in other types of tumors.
Materials and methods
Cell culture
BaF/3 control cells, Bcr-Abl1-expressing BaF/3-p210 cells, and
BaF/3 cells expressing IM-resistant Bcr-Abl1 mutants were a
kind gift of Dr Druker (Griswold et al., 2006). The TCC-S cell
line derived from a CML patient in blast crisis and that
expresses mainly the p210 form of Bcr-Abl1 and, to a lower
extent, also the p190 form of the oncoprotein (Van et al., 2005)
was obtained from the American Type Culture Collection
(Manassas, VA, USA). These cell lines were grown in RPMI
supplemented with 10% FCS, L-glutamine, and penicillin
streptomycin. In the case of the BaF/3 cells, 10% WEHI-
conditioned medium was added to the culture medium as a
source of murine IL-3, whereas growth of Bcr-Abl1-expressing
BaF/3 cells was independent of growth factors. Primary CML
CD34þ cells and control CD34þ cells from umbilical cord
blood, obtained after informed consent, were selected and
cultured as described (Andreu et al., 2005). All media, serum,
and supplements were from Invitrogen Life Technologies
(Paisley, UK). When indicated, cell lines were treated with the
tyrosine-kinase inhibitor IM (STI571, Gleevec, generously
provided by Dr Elisabeth Buchdunger, Novartis, Basel, Switzer-
land). The reversible proteasome inhibitor Btz (PS341, Velcade)
was kindly supplied by Millenium Pharmaceuticals (Cambridge,
MA, USA). Both drugs were administered as a single dose at the
beginning of the experiment. To inhibit caspase activity, cells
were pre-treated for 1h with 100mM of the pan-caspase inhibitor
z-Val-Ala-DL-Asp(OMe)-ﬂuoromethylketone (z-VAD) (Bachem,
Bubendorf, Switzerland). Cell lines were seeded at a density of
1 105/ml and viable cells (assessed by Trypan blue exclusion)
were counted at different time points as indicated.
Analysis of the cell cycle and apoptosis by ﬂow cytometry
Cell-cycle proﬁles were obtained by PI staining using the DNA
Prep Reagent System (Beckman Coulter, Fullerton, CA,
USA). Brieﬂy, 5 105 cells were washed twice in cold PBS,
ﬁxed in ice-cold 80% ethanol and kept at 20 1C until further
analyzed. For a detailed analysis of the cell-cycle distribution,
cells were labeled for 30min with 0.5 mM of the nucleotide
analog EdU using the Click-iT EdU Flow Cytometry Assay
(Invitrogen, Eugene, OR, USA) following the manufacturer’s
instructions. The double staining with EdU and PI allows the
quantiﬁcation of the cell populations in the G0/G1, S, and G2/M
phases of the cell cycle. Phosphatidylserine exposure was used
as an indication of apoptosis and quantiﬁed by Annexin-V/PI
staining with Annexin-V-FLUOS Stainning kit (Roche,
Mannheim, Germany). PI staining of un-ﬁxed cells to quantify
the sub-G0/G1 population was also used as a measure of
apoptosis. Cells were analyzed in a FC500 ﬂow cytometer
(Beckman Coulter), using CytomicsTM RXP and WinMDI
programs.
Western blot analysis
For analysis of protein expression, cell extracts were prepared
and analyzed as earlier described (Poch et al., 2007). We used
primary antibodies against the following proteins: p27Kip1
(C19 and F8), p21Cip1 (C19), c-Myc (N262), CycA (C19), and
NF-kB2 (k27) from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); p45Skp2 (2B12) from Zymed (San Francisco, CA,
USA); Rb (G3-245) from BD Biosciences-Pharmingen
(San Jose, CA, USA); and b-tubulin from Sigma (St Louis,
MO, USA). Horseradish peroxidase-conjugated secondary
antibodies were from Pierce (Rock-Ford, IL, USA). Blots
were developed using the enhanced chemiluminescence system
(ECL Plus, Amersham Bioscience, Little Chalfont, UK). Rb
phosphorylation was analyzed as described earlier (Andreu
et al., 2005). Samples were separated in 20 20 cm2 PAGE
gels. We used the QuantityOne software (Bio-Rad, Hercules,
CA, USA) to quantify the intensity of the bands.
Electrophoretic mobility shift assay
To obtain nuclear extracts, 10 106 cells were collected,
washed in PBS, and centrifuged at 500 g at 4 1C. The pellet
was resuspended in cytosol extraction buffer containing 5mM
Na2HPO4 pH 7.4, 50mM NaCl, 150mM sucrose, 5mM KCl,
2mM DTT, 1mM MgCl2, 0.5mM CaCl2, and 0.1mM PMSF
(phenylmethylsulphonyl ﬂuoride) with 0.1% NP-40, were left
on ice for 3min, and centrifuged at 1000 g, 10min at 4 1C in a
refrigerated Eppendorf 5417 R centrifuge with a ﬁxed angle
rotor. The pellet was gently resuspended again in the same
buffer without NP-40 and deposited on a solution containing
30% sucrose, 2.5mM Tris–HCl pH 7.4, and 10mM NaCl,
prepared fresh for each sample and centrifuged at 1000 g,
10min at 4 1C. The pellet was resuspended in nuclear
extraction buffer (50mM Tris–HCl pH 7.4, 300mM NaCl,
and 0.5% Triton X-100). Once resuspended, the samples were
incubated on ice 20–30min, subsequently centrifuged at
10 000 g, 10min at 4 1C, and the supernatant corresponding
to the nuclear fraction was collected and quantiﬁed with the
DC protein assay (Bio-Rad). The DNA-binding activity of
NF-kB in these extracts was analyzed by electrophoretic
mobility shift assay using the DIG Gel Shift Kit, Second
Generation (Roche) and following the manufacturer’s instruc-
tions. The nuclear extracts (10 mg) were incubated with
Digoxigenin-labeled double-stranded DNA oligonucleotides
corresponding to the consensus-binding site for NF-kB 50-AG
TTGAGGGGACTTTCCCAGGC-30 (Dai et al., 2004).
Statistical analysis
Microsoft Excel and GraphPadPrism were used to analyze the
data and calculate IC50 values from dose-response plots. To
analyze the possible synergism between IM and Btz on BaF/
3-p210 cells, we used the CalcuSyn software (Biosoft, Cam-
bridge, UK) based on the Chou and Talalay method (Chou
and Talalay, 1984).
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